皇家华人

header-logo
GettyImages-609179959-hero
Cardiovascular Center

Auchampach Lab

John A. Auchampach, PhD

johnauchampach
Principal Investigator; Professor, Vice Chair, Pharmacology and Toxicology
jauchamp@mcw.edu

Dr. Auchampach is a professor in the Department of Pharmacology. He leads an NIH-funded laboratory focused on ischemic heart disease, cardiac regeneration, and drug development. 

Our laboratory studies adenosine signaling via its four G protein-coupled receptors during cardiovascular disease. We utilize mice and rats as our model system. I am involved in generating and characterizing new genetic mouse models with global and tissue-specific deletion of specific adenosine receptor subtypes. Other important aspects of my research involve assessing cardiac function (pressure-volume analyses; echocardiography) and conducting surgeries to induce myocardial infarction in rodents. Our laboratory has recently formed a new collaboration with Dr. John Lough in the Department of Cell Biology. The goal of this project using novel genetic mouse models is to test the hypothesis that inhibition of the acetyl transferase Tip60 during myocardial infarction will promote more efficient regeneration by permitting surviving cardiomyocytes to re-enter the cell cycle.

Tina Wan


Tina Wan, PhD
Research Scientist
twan@mcw.edu

 

 

Elizabeth Gizewski
Elizabeth Gizewski, BS
Research Technologist III
egizewsk@mcw.edu

I received my Degree from the University of Wisconsin-Madison. I have been working with Dr. Auchampach’s research group for the past 10 years. My role has been to characterize new synthetic ligands for adenosine receptors utilizing various biochemical assays including radioligand binding, cAMP accumulation, and [35S]GTPγS binding assays. I have made several important contributions to our research program working with research chemists at the NIH and Leiden University in the Netherlands. I have assisted with the development of new selective agonists for the A3 adenosine receptor, which have promise as drug therapy for many different inflammatory disorders and chronic neuropathic pain. I have also contributed to the development and characterization of an exciting new class of ligands for the A3 adenosine receptor called positive A3 adenosine receptor allosteric modulators.

Shraddha Nayak

Shraddha Nayak, BS
Graduate Research Assistant
snayak@mcw.edu

I am a PhD graduate student in the Department of Pharmacology completing my thesis work in Dr. Auchampach’s laboratory. My project involves characterizing a new line of rats in which the A2B adenosine receptor gene has been genetically disrupted using the zinc finger nuclease strategy. The rat line was created on the Dahl salt-sensitive genetic background. My work has led to better understanding of the participation of A2B adenosine receptor signaling during cardiovascular diseases including hypertension and diabetes.

Recent Publications

  • (Pradhan B, Pavan M, Fisher CL, Salmaso V, Wan TC, Keyes RF, Rollison N, Suresh RR, Kumar TS, Gao ZG, Smith BC, Auchampach JA, Jacobson KA.) J Med Chem. 2024 Jul 25;67(14):12221-12247 PMID: 38959401 PMCID: PMC11636968 SCOPUS ID: 2-s2.0-85197620924 07/03/2024

  • (Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA.) ACS Pharmacol Transl Sci. 2024 Jul 12;7(7):2154-2173 PMID: 39022354 PMCID: PMC11249627 07/18/2024

  • (Fisher CL, Pavan M, Salmaso V, Keyes RF, Wan TC, Pradhan B, Gao ZG, Smith BC, Jacobson KA, Auchampach JA.) Mol Pharmacol. 2024 Feb 15;105(3):213-223 PMID: 38182432 PMCID: PMC10877738 SCOPUS ID: 2-s2.0-85185222449 01/06/2024

  • (Wang X, Kulik K, Wan TC, Lough JW, Auchampach JA.) bioRxiv. 2024 Jan 13 PMID: 38260622 PMCID: PMC10802610 01/23/2024

  • (Tosh DK, Pavan M, Cronin C, Pottie E, Wan TC, Chen E, Lewicki SA, Campbell RG, Gao ZG, Auchampach JA, Stove CP, Liang BT, Jacobson KA.) ACS Pharmacology and Translational Science. 12 July 2024;7(7):2154-2173 SCOPUS ID: 2-s2.0-85195801024 07/12/2024

  • (Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA.) ACS Pharmacol Transl Sci. 2023 Sep 08;6(9):1288-1305 PMID: 37705595 PMCID: PMC10496144 09/14/2023

  • (Gao ZG, Auchampach JA, Jacobson KA.) Purinergic Signal. 2023 Sep;19(3):523-550 PMID: 36538251 PMCID: PMC9763816 SCOPUS ID: 2-s2.0-85173914165 12/21/2022

  • (Wang X, Wan TC, Kulik KR, Lauth A, Smith BC, Lough JW, Auchampach JA.) Dis Model Mech. 2023 May 01;16(5) PMID: 36341679 PMCID: PMC9672930 SCOPUS ID: 2-s2.0-85141362492 11/08/2022

  • (Tosh DK, Fisher CL, Salmaso V, Wan TC, Campbell RG, Chen E, Gao ZG, Auchampach JA, Jacobson KA.) ACS Pharmacology and Translational Science. 8 September 2023;6(9):1288-1305 SCOPUS ID: 2-s2.0-85168520378 09/08/2023

  • (Fallot LB, Suresh RR, Fisher CL, Salmaso V, O'Connor RD, Kaufman N, Gao ZG, Auchampach JA, Jacobson KA.) J Med Chem. 2022 Nov 24;65(22):15238-15262 PMID: 36367749 PMCID: PMC10354740 SCOPUS ID: 2-s2.0-85141945462 11/12/2022

  • (Fisher CL, Fallot LB, Wan TC, Keyes RF, Suresh RR, Rothwell AC, Gao ZG, McCorvy JD, Smith BC, Jacobson KA, Auchampach JA.) ACS Pharmacol Transl Sci. 2022 Aug 12;5(8):625-641 PMID: 35983277 PMCID: PMC9380209 08/20/2022

  • (Auchampach J, Han L, Huang GN, Kühn B, Lough JW, O'Meara CC, Payumo AY, Rosenthal NA, Sucov HM, Yutzey KE, Patterson M.) Am J Physiol Heart Circ Physiol. 2022 Apr 01;322(4):H579-H596 PMID: 35179974 PMCID: PMC8934681 SCOPUS ID: 2-s2.0-85127729067 02/19/2022

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.